The COVID-19 pandemic, however, might have given the industry the much-needed push to increase the adoption of robotics to ensure continuation of operations amid lockdown restrictions.
Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.